Clinical review report: Fluticasone Propionate (Aermony Respiclick) (Teva Canada Innovation) indication : for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older
The objective of this review is to perform a systematic review of the beneficial and harmful effects of Fp MDPI 55 mcg, 113 mcg, and 232 mcg for the maintenance treatment of steroid-responsive bronchial asthma in patients 12 years and older
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
January 2019, 2019
|
| Edition: | Final (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of Fp MDPI 55 mcg, 113 mcg, and 232 mcg for the maintenance treatment of steroid-responsive bronchial asthma in patients 12 years and older |
|---|---|
| Physical Description: | 1 PDF file (135 pages) illustrations |